Here we are at the midpoint of 2016 already. Time to look back on the past six months—and some of the top stories of the year so far.
The following represent a cross-section of what Xconomy offers on a daily basis:... Read more »
[Corrected 6/30/16, 2:49 p.m. See below.] Google Capital’s $46.35 million investment in publicly traded Care.com, announced Wednesday, marked a departure from the firm’s usual bets on late-stage private companies and illustrated how the traditional lines in the venture capital... Read more »
Roboticists covered a sweeping range of topics at Xconomy’s annual Robo Madness West conference last week, from the ethics of artificial intelligence to the powerful impact of robots that have faces.
Two themes ran through all the panel discussions, whether they... Read more »
Moderna Therapeutics still hasn’t produced data in humans supporting its technology, which is meant to turn our bodies into little drugmaking factories. But the Cambridge, MA-based company nonetheless keeps grabbing the attention, and cash, of other drugmakers.
Moderna said today that... Read more »
The Boston-area cybersecurity scene is ripe with acquisition targets. IBM bought incident-response firm Resilient Systems earlier this year. Now, Cisco Systems says it is acquiring CloudLock, a Waltham, MA-based cloud security company, for $293 million in cash and stock, plus... Read more »
[Updated 6/28/16, 12:50pm. See below.] PureTech Health starts companies in cutting-edge areas of biomedical science and often owns them outright. Its latest aims to create software that listens for warning signs of depression in people’s speech patterns.
The unveiling... Read more »
A new wave of drugs has changed the way hepatitis C is treated. Regulus Therapeutics has not been part of that wave, but the company’s plans to join it took a big hit this afternoon.
Waltham, MA-based Forum Pharmaceuticals, which spent more than decade pursuing a drug for Alzheimer’s and other neurological diseases, is shutting down, Xconomy has learned.
According to a Forum spokesperson, the company will be closed “by the end of the week.” The... Read more »
Just another billion-dollar exit for a Massachusetts company most people have never heard of. This one has an interesting backstory, in a field rife with consolidation and would-be deals.
[Updated 6/27/16, 2:13 p.m., to include Hack/secure news.] It’s time to catch up on a few recent developments in the Boston tech world. We’ve got funding news, the latest on the DraftKings saga in New York, shuttered co-working spaces,... Read more »
Some comparisons between business and sports are cliché. But when it comes to leadership in cybersecurity, having a CEO who knows how to play defense can be pretty relevant.
We had a grand old time at this week’s blowout Boston event, Influx. Leaders from Akamai, MIT, Harvard, and other venerable institutions met with top folks from GE Ventures, IBM Watson Health, Dell-EMC, and startups and investors, to talk about... Read more »
It’s a week for the history books. The United Kingdom voted to leave the European Union last night, triggering worldwide financial fears and, perhaps, a breakup of the U.K. itself. Closer to home, Cleveland (pictured) celebrated LeBron James & the Cavaliers’... Read more »
Google Fiber plans to acquire Webpass in a deal that trims the ranks of independent Internet service providers—an industry already maligned for its lack of competition—but ultimately could boost consumer access to high-speed Internet.
San Francisco-based Webpass has spent the past... Read more »
Circle Internet Financial aims to make transferring money to a friend across town or on the other side of the world as easy as sending a text message. That plan got a big boost with Wednesday’s announcement of a $60 million... Read more »
Engineered organ developer Harvard Apparatus Regenerative Technology has done all it can to disassociate itself from the surgeon Paolo Macchiarini. The Holliston, MA-based company is now known as Biostage (NASDAQ: BSTG), uses a different technology, is led by a different... Read more »
So far, the story of IBM Watson Health has been mostly about growth and potential. Today, it’s more about action.
LightCyber, a cybersecurity company that specializes in detecting hackers once they’ve breached the outer defenses of a data network, announced today it raised $20 million in a Series B financing round.
The venture round was led by Claltech, an Israeli... Read more »
Because public investors have had a more discerning attitude toward biotech IPOs this year, insiders have had to step up to help their companies go public. One extreme example is Selecta Biosciences, which just priced its offering late Tuesday with its... Read more »
There is no shortage of companies out there trying to tweak our immune systems in one way or another to treat diseases like cancer. Today, IFM Therapeutics, a new startup seeded by Boston firm Atlas Venture, has joined the fray.
IFM,... Read more »
[Updated, 6/21/16, 5:40pm. See below.] Despite worries about conflict of interest, a National Institutes of Health committee that oversees the use of gene therapy and other cutting edge biomedical technologies voted today to let researchers move ahead with a... Read more »
A few recent moves by Boston-area cybersecurity firms illustrate the various ways the sector’s members (and related companies) are trying to build their businesses and bolster measures to counter cyber threats:
We’re only one day away from Influx, Xconomy’s big event highlighting Boston’s newest influencers and innovators, which will take place tomorrow afternoon (June 22) at the Science Museum. And for you late decision-makers, you’re almost out of time to save... Read more »
[Corrected, 6/21/06, 10:49 am. See below.] Internet billionaire Sean Parker’s new cancer immunotherapy institute didn’t waste time putting its $250 million to use in unexpected ways.
The San Francisco-based institute, part of a massive philanthropic effort by former Facebook... Read more »
Executive VP of R&D, Biogen Idec
Co-founder and CEO, PureTech
CEO, Cambridge Innovation Center
Partner, North Bridge Venture Partners
President and CEO, FORUM Pharmaceuticals
Founder and CEO, Acme Packet
Managing Dir. of Life Sciences, Hercules Technology Growth Capital
Distinguished Lecturer, Sloan School of Management at MIT
Baker Foundation Professor, Business Administration, Harvard Business School
Chairman and CEO, Nanobiosym Diagnostics Inc.